UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000022824
Receipt number R000026308
Scientific Title Comprehensive assessment of the association between exosome-derived miRNA expression in gastric juice and functional dyspepsia
Date of disclosure of the study information 2016/06/21
Last modified on 2020/01/31 15:32:07

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Comprehensive assessment of the association between exosome-derived miRNA expression in gastric juice and functional dyspepsia

Acronym

Exosome-derived miRNA expressions in gastric juice of functional dyspepsia patients

Scientific Title

Comprehensive assessment of the association between exosome-derived miRNA expression in gastric juice and functional dyspepsia

Scientific Title:Acronym

Exosome-derived miRNA expressions in gastric juice of functional dyspepsia patients

Region

Japan


Condition

Condition

Functional dyspepsia

Classification by specialty

Medicine in general Gastroenterology Psychosomatic Internal Medicine

Classification by malignancy

Others

Genomic information

YES


Objectives

Narrative objectives1

The aim of this study is to identify the specific exosome-derived miRNA expression in gastric juice of fuctional dyspepsia patients.

Basic objectives2

Others

Basic objectives -Others

The analysis of pathophysiology

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The expression of exosome-derived miRNA in gastric juice

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

The patients underwent esophagogastroduodenoscopy and analysis of anti-Helicobacter pylori (H.pylori) IgG antibody. The patients who wrote questionaire and informed consent.

Key exclusion criteria

The patients who have severe diseases of heart, lung, liver, kidney, thyroid, mental, and cancer.
The patients who have organic diseases of upper gastrointestinal tract; gastric and duodenal ulcer, gastric cancer and adenoma
The patients who had history of operarion in abdomen
The patients who take anti-acid drugs
The patients who take NSAIDs
The patients who take anti-coagulants
The patients who did not have assement of H.pylori eradication
The patients who had unknown history of H.pylori eradication
H.pylori IgG showed false-negative

Target sample size

300


Research contact person

Name of lead principal investigator

1st name Fumio
Middle name
Last name TANAKA

Organization

Osaka City University Graduate School of Medicine

Division name

Gastroenterology

Zip code

5458585

Address

1-4-3 Asahimachi, Abeno-ku, Osaka City, Osaka

TEL

0666453811

Email

m2079981@med.osaka-cu.ac.jp


Public contact

Name of contact person

1st name Fumio
Middle name
Last name TANAKA

Organization

Osaka City University Graduate School of Medicine

Division name

Gastroenterology

Zip code

5458585

Address

1-4-3 Asahimachi, Abeno-ku, Osaka City, Osaka

TEL

0666453811

Homepage URL


Email

m2079981@med.osaka-cu.ac.jp


Sponsor or person

Institute

Osaka City University

Institute

Department

Personal name



Funding Source

Organization

Japan Society for the Promotion of Science

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Osaka City University Hospital Certified Review Board

Address

Abeno Medix 6F, 1-2-7, Asahimachi, Abeno-ku, Osaka

Tel

06-6646-6125

Email

ethics@med.osaka-cu.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 06 Month 21 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

22

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2016 Year 04 Month 20 Day

Date of IRB

2016 Year 05 Month 30 Day

Anticipated trial start date

2016 Year 04 Month 20 Day

Last follow-up date

2020 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

The results of this study was published.


Management information

Registered date

2016 Year 06 Month 21 Day

Last modified on

2020 Year 01 Month 31 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026308


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name